Quantitative proteomics identifies biomarkers to distinguish pulmonary from 
head and neck squamous cell carcinomas by immunohistochemistry

Richter, A.; Fichtner, A.; Joost, J.; Brockmeyer, P.; Kauffmann, P.; Schliephake, H.; Hammerstein‐Equord, A.; Kueffer, S.; Urlaub, H.; Oellerich, T.; Ströbel, P.; Bohnenberger, H.; Bremmer, F.

doi:10.1002/cjp2.244

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry

MPS-Authors

/persons/resource/persons15947

Urlaub, H.
Research Group of Bioanalytical Mass Spectrometry, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

3384938.pdf
(Publisher version), 3MB

Supplementary Material (public)

There is no public supplementary material available

Citation

Richter, A., Fichtner, A., Joost, J., Brockmeyer, P., Kauffmann, P., Schliephake, H., et al. (2022). Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry. The Journal of Pathology: Clinical Research, 8(1), 33-47. doi:10.1002/cjp2.244.

Cite as: https://hdl.handle.net/21.11116/0000-000A-CA9B-4

Abstract

The differentiation between a pulmonary metastasis and a newly developed squamous cell carcinoma of the lung
in patients with prior head and neck squamous cell carcinoma (HNSCC) is difficult due to a lack of biomarkers
but is crucially important for the prognosis and therapy of the affected patient. By using high-resolution mass
spectrometry in combination with stable isotope labelling by amino acids in cell culture, we identified 379 pro-
teins that are differentially expressed in squamous cell carcinomas of the lung and the head and neck. Of those,
CAV1, CAV2, LGALS1, LGALS7, CK19, and UGDH were tested by immunohistochemistry on 194 tissue samples
(98 lung and 96 HNSCCs). The combination of CAV1 and LGALS7 was able to distinguish the origin of the squa-
mous cell carcinoma with high accuracy (area under the curve 0.876). This biomarker panel was tested on a
cohort of 12 clinically classified lung tumours of unknown origin after HNSCC. Nine of those tumours were
immunohistochemically classifiable.